

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of ^{177}Lu -DOTA-octreotate in Neuroendocrine Tumor Cells

Rashmi G. Shah, Marine A. Merlin, Samuel Adant, Fayçal Zine-Eddine, Jean-Mathieu and Girish M. Shah

Supplementary Figs: Shah, RG: "Chemotherapy-induced ...cells." (Manuscript ID: 1036587)




Figure S1. Increased uptake of LuTate in drug-treated cells was specific to SSTR2 binding and not due to non-specific adsorption to cells. BON-1 cells were treated for 24 h with 10 μM TEM, 10 μM 5-FU or 50 $\mu\text{g/mL}$ STZ and uptake of ^{177}Lu Tate or ^{177}Lu -DTPA was measured after 4 days, as described for Fig. 5A. The uptake of ^{177}Lu Tate was increased 2 to 8-fold with different drugs, and this was between 5 to 20-times stronger than the non-specific adsorption of membrane impermeable ^{177}Lu -DTPA.




Figure 2. Senescence induced by 5-FU can be blocked by mTOR inhibitor rapamycin. BON-1 cells were treated with 50 nM of Rapamycin (or mock treated) 5 h before treatment with 5 μM 5-FU. Cells were washed at 24h and allowed to recover in fresh medium for 4 days prior to staining for the senescence-associated β -galactosidase. .